UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 13, 2016
bluebird bio, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE |
| 001-35966 |
| 13-3680878 |
|
|
|
|
|
(State or other jurisdiction of |
| (Commission File Number) |
| (I.R.S. Employer |
|
|
|
150 Second Street Cambridge, MA |
| 02141 |
|
|
|
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
On October 13, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing its research and development strategies for its gene therapy programs, including bluebird’s progress with manufacturing process improvements, planned changes to its HGB-206 clinical trial of its Lenti-Globin product candidate for the treatment of severe sickle cell disease, and regulatory updates for its Lenti-Globin product candidate for the treatment of transfusion-dependent beta-thalassemia.
The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
|
99.1 |
| Press release issued by bluebird bio, Inc. on October 13, 2016. | |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: October 13, 2016 | bluebird bio, Inc.
|
| ||
| By: | /s/ Jason F. Cole |
| |
|
| Jason F. Cole |
| |
|
| Chief Legal Officer |
| |
Exhibit No. |
| Description |
|
99.1 |
| Press release issued by bluebird bio, Inc. on October 13, 2016. | |
